n-(3-(aminomethyl)benzyl)acetamidine has been researched along with Atrophy in 1 studies
N-(3-(aminomethyl)benzyl)acetamidine: structure in first source
N-[3-(aminomethyl)benzyl]acetamidine : An aralkylamine that is Nbenzylacetamidine substituted at position 3 on the benzene ring by an aminomethyl group. An inhibitor of nitric oxide synthase.
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Roe, ND | 1 |
| Ren, J | 1 |
1 other study available for n-(3-(aminomethyl)benzyl)acetamidine and Atrophy
| Article | Year |
|---|---|
Akt2 knockout mitigates chronic iNOS inhibition-induced cardiomyocyte atrophy and contractile dysfunction despite persistent insulin resistance.
Topics: Amidines; Animals; Apoptosis; Atrophy; Benzylamines; Calcium; Echocardiography; Glucose; Glucose Tol | 2011 |